Fruzaqla (fruquintinib)

News alerts, weekly reports and conference planners

Company:

Eli Lilly, Hutchmed, Takeda

Drug class:

VEGFR inhibitor

Related drugs:

‹

›

No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	fruquintinib Sensitive: A1 - Approval fruquintinib Sensitive : A1	fruquintinib Sensitive: A1 - Approval fruquintinib Sensitive : A1
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	fruquintinib Sensitive: A2 - Guideline fruquintinib Sensitive : A2	fruquintinib Sensitive: A2 - Guideline fruquintinib Sensitive : A2
No biomarker	Colon Cancer	No biomarker	Colon Cancer	fruquintinib Sensitive: A2 - Guideline fruquintinib Sensitive : A2	fruquintinib Sensitive: A2 - Guideline fruquintinib Sensitive : A2
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	fruquintinib Sensitive: B - Late Trials fruquintinib Sensitive : B	fruquintinib Sensitive: B - Late Trials fruquintinib Sensitive : B
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	sintilimab + fruquintinib Sensitive: B - Late Trials sintilimab + fruquintinib Sensitive : B	sintilimab + fruquintinib Sensitive: B - Late Trials sintilimab + fruquintinib Sensitive : B
MSI-H/dMMR	Colon Cancer	MSI-H/dMMR	Colon Cancer	fruquintinib Sensitive: C2 – Inclusion Criteria fruquintinib Sensitive : C2	fruquintinib Sensitive: C2 – Inclusion Criteria fruquintinib Sensitive : C2
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	sintilimab + fruquintinib Sensitive: C2 – Inclusion Criteria sintilimab + fruquintinib Sensitive : C2	sintilimab + fruquintinib Sensitive: C2 – Inclusion Criteria sintilimab + fruquintinib Sensitive : C2
FANCA mutation	Colorectal Cancer	FANCA mutation	Colorectal Cancer	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3
NOTCH1 mutation	Colorectal Cancer	NOTCH1 mutation	Colorectal Cancer	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3
STAG2 mutation	Colorectal Cancer	STAG2 mutation	Colorectal Cancer	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3
AMER1 mutation	Colorectal Cancer	AMER1 mutation	Colorectal Cancer	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3
DNMT3A mutation	Colorectal Cancer	DNMT3A mutation	Colorectal Cancer	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3
ETV5 mutation	Colorectal Cancer	ETV5 mutation	Colorectal Cancer	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3
EWSR1 mutation	Colorectal Adenocarcinoma	EWSR1 mutation	Colorectal Adenocarcinoma	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3
IKBKE mutation	Colorectal Cancer	IKBKE mutation	Colorectal Cancer	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3
TCF7L2 mutation	Colorectal Cancer	TCF7L2 mutation	Colorectal Cancer	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib + fruquintinib Sensitive: C3 – Early Trials gefitinib + fruquintinib Sensitive : C3	gefitinib + fruquintinib Sensitive: C3 – Early Trials gefitinib + fruquintinib Sensitive : C3
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	fruquintinib + geptanolimab Sensitive: C3 – Early Trials fruquintinib + geptanolimab Sensitive : C3	fruquintinib + geptanolimab Sensitive: C3 – Early Trials fruquintinib + geptanolimab Sensitive : C3
EGFR negative + ALK negative	Lung Non-Squamous Non-Small Cell Cancer	EGFR negative + ALK negative	Lung Non-Squamous Non-Small Cell Cancer	sintilimab + fruquintinib Sensitive: C3 – Early Trials sintilimab + fruquintinib Sensitive : C3	sintilimab + fruquintinib Sensitive: C3 – Early Trials sintilimab + fruquintinib Sensitive : C3
PD-L1 expression	Gastrointestinal Stromal Tumor	PD-L1 expression	Gastrointestinal Stromal Tumor	sintilimab + fruquintinib Sensitive: C3 – Early Trials sintilimab + fruquintinib Sensitive : C3	sintilimab + fruquintinib Sensitive: C3 – Early Trials sintilimab + fruquintinib Sensitive : C3
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	sintilimab + fruquintinib Sensitive: C3 – Early Trials sintilimab + fruquintinib Sensitive : C3	sintilimab + fruquintinib Sensitive: C3 – Early Trials sintilimab + fruquintinib Sensitive : C3
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	sintilimab + fruquintinib Sensitive: C3 – Early Trials sintilimab + fruquintinib Sensitive : C3	sintilimab + fruquintinib Sensitive: C3 – Early Trials sintilimab + fruquintinib Sensitive : C3
TMB-H	Colorectal Cancer	TMB-H	Colorectal Cancer	sintilimab + fruquintinib Sensitive: C4 – Case Studies sintilimab + fruquintinib Sensitive : C4	sintilimab + fruquintinib Sensitive: C4 – Case Studies sintilimab + fruquintinib Sensitive : C4
MSI-H/dMMR + KRAS G12D	Colon Cancer	MSI-H/dMMR + KRAS G12D	Colon Cancer	fruquintinib Sensitive: C4 – Case Studies fruquintinib Sensitive : C4	fruquintinib Sensitive: C4 – Case Studies fruquintinib Sensitive : C4

Fruzaqla (fruquintinib)

Associations
(24)

Associations
(24)

Fruzaqla (fruquintinib)

Associations(24)

Associations(24)

Associations
(24)

Associations
(24)